The Effects of Calcitriol Therapy on Serum Interleukin-1,Interleukin-6 and Tumour Necrosis Factor-α Concentrations in Post-menopausal Patients with Osteoporosis
Free accessResearch articleFirst published online November, 2004
The Effects of Calcitriol Therapy on Serum Interleukin-1,Interleukin-6 and Tumour Necrosis Factor-α Concentrations in Post-menopausal Patients with Osteoporosis
Seventy post-menopausal women with osteoporosis were randomized into two groups: 40 patients received calcitriol (0.5 μg/day) and calcium (1000 mg/day); and 30 control patients received calcium (1000 mg/day) alone. Thirty healthy women formed the healthy control group. Bone mineral density (BMD) and serum interleukin (IL)-1, IL-6 and tumour necrosis factor-α (TNF-α) concentrations were measured at baseline and after 6 months of treatment. Calcitriol treatment for 6 months significantly increased BMD and reduced serum IL-1 and TNF-α concentrations compared with no significant changes in patients treated with calcium alone. Both treatments increased serum calcium and decreased parathyroid hormone concentrations. The healthy control group had a significantly lower IL-6 concentration than the post-menopausal women with osteoporosis. We have shown that calcitriol was an effective treatment for osteoporosis. Significant reductions in serum IL-1 and TNF-α concentrations suggest that, in addition to increasing the absorption of calcium, calcitriol may directly affect bone metabolism via cytokines.
KanisJA: Pathogenesis of osteoporosis and fracture. In: Osteoporosis (KanisJA, ed). London: Blackwell Science, 1997; pp22–55.
2.
DelaneyMFLe BoffMS: Metabolic Bone Disease. In: Kelly's Textbook of Rheumatology (RuddySHarrisEDSledgeCB, eds). Philadelphia: WB Saunders Company, 2001; pp1635–1645.
3.
ReginsterJYHalkinVHenrotinYGossetC: Treatment of osteoporosis: Role of bone-forming agents. Osteoporosis Int1999; 9 (suppl 2): 91–96.
4.
Who are candidates for prevention and treatment for osteoporosis?Osteoporosis Int1997; 7: 1–6.
5.
KanisJAGlüerCC: An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporosis Int2000; 11: 192–202.
6.
PrinceRLDickIMLemmonJRandellD: The pathogenesis of age-related osteoporotic fracture: Effects of dietary calcium deprivation. J Clin Endocrinol Metab1997; 82: 260–264.
7.
KokaSPetroTMReinhardtRA: Estrogen inhibits interleukin-1 beta-induced interleukin-6 production by human osteoblast-like cells. J Interferon Cytokine Res1998; 18: 479–483.
8.
SeemanE: Periosteal bone formation—a neglected determinant of bone strength. N Engl J Med2003; 349: 320–323.
9.
RiggsBL: Role of the vitamin D-endocrine system in the pathophysiology of postmenopausal osteoporosis. J Cell Biochem2003; 88: 209–215.
10.
ResnickD: Osteoporosis. In: Diagnosis of Bone and Joint Disorders (ResnickD, ed). Philadelphia: WB Saunders Company, 2002; pp1783–1860.
11.
LipsP: Vitamin D deficiency and osteoporosis: The role of vitamin D deficiency and treatment with vitamin D and analogues in the prevention of osteoporosis-related fractures. Eur J Clin Invest1996; 26: 436–442.
12.
NutiRBonucciEBrancaccioDGallagherJCGennariCMazzuoliG: The role of calcitriol in the treatment of osteoporosis. Calcif Tissue Int2000; 66: 239–240.
13.
Kyriakidou-HimonasMAloiaJFYehJK: Vitamin D supplementation in post-menopausal black women. J Clin Endocrinol Metab1999; 84: 3988–3990.
14.
BorregoMJMartin-MaloAAlmadenYRodriguezMAljamaPFelsenfeldAJ: Effect of calcitriol and age on recovery from hypocalcemia in hemodialysis patients. Am J Kidney Dis1999; 34: 456–463.
15.
CenciSToraldoGWeitzmannMNRoggiaCGaoYQianWP: Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci U S A2003; 100: 10405–10410.
16.
KomarovaSVSmithRJDixonSJSimsSMWahlLM: Mathematical model predicts a critical role for osteoclast autocrine regulation in the control of bone remodeling. Bone2003; 33: 206–215.
17.
KimbleRBSrivastavaSRossFPMatayoshiAPacificiR: Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1 and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J Biol Chem1996; 271: 28890–28897.
18.
NguyenLDewhirstFEHauschkaPVStashenkoP: Interleukin-1 beta stimulates bone resorption and inhibits bone formation in vivo. Lymphokine Cytokine Res1991; 10: 15–21.
19.
KitazawaRKimbleRBVanniceJLKungVTPacificiR: Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J Clin Invest1994; 94: 2397–2406.
20.
FontovaRGutierrezCVendrellJBrochMVendrellISimonI: Bone mineral mass is associated with interleukin-1 receptor autoantigen and TNF-alpha gene polymorphisms in post-menopausal Mediterranean women. J Endocrinol Invest2002; 25: 684–690.
21.
AbrahamsenBOBonnevie-NielsenVEbbesenEBGramJBeck-NielsenH: Cytokines and bone loss in a 5-year longitudinal study. Hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: The Danish Osteoporosis Prevention Study. J Bone Mineral Res2000; 15: 1545–1554.
22.
LindsayR. Risk assessment using bone mineral density determination. Osteoporosis Int1998; 8 (suppl 1): S28–S31.
23.
Review of the evidence for prevention, diagnosis and treatment. Osteoporosis Int1998; 8 (suppl 4): S7–S80.
24.
RossPD: Clinical consequences of vertebral fracture. Am J Med1997; 103 (suppl 2): 30S–43S.
25.
BonnerFJChesnutCHFitzsimmonsA: Osteoporosis. In: Rehabilitation Medicine: Principles and Practice, 3rd edn (BruceMG, ed). Philadelphia, USA: Lippincott, Williams and Wilkins, 1997; pp1453–1475.
26.
GallagherJCRiggsBL: Action of 1, 25-dihydroxyvitamin D3 on calcium balance and bone turnover and its effect on vertebral fracture rate. Metabolism1990; 39: 30–34.
27.
GallagherJCGoldgarD: Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med1990; 113: 649–655.
28.
ŞenocakÖPekerÖAkalinE: Calcitriol and vitamin D3 treatment results in post-menopausal osteoporosis. Osteoporosis Int1998; 8: 116.
29.
BetticaPBevilacquaMVagoTNorbiatoG: High prevalence of hypovitaminosis D among free-living postmenopausal women referred to an osteoporosis outpatient clinic in northern Italy for initial screening. Osteoporosis Int1999; 9: 226–229.
30.
AvioliLV: Vitamin D and the D-hormones, alfacalcidol and calcitriol, as therapeutic agents for osteoporotic populations. Calcif Tissue Int1999; 65: 292–294.
31.
KriegMAJacquetAFBremgartnerMCuttelodSThiebaudDBurckhardtP: Effect of supplementation with vitamin D3 and calcium on quantitative ultrasound of bone in elderly institutionalized women: a longitudinal study. Osteoporosis Int1999; 9: 483–488.
32.
MeunierPJ: Calcium, vitamin D and vitamin K in the prevention of fracture due to osteoporosis. Osteoporosis Int1999; 9 (suppl 2): S48–S52.
33.
OttSMChesnutCH: Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med1989; 110: 267–274.
34.
van HoofHJvan der MoorenMJSwinkelsLMSweepCGMerkusJMBenraadTJ: Female sex hormone replacement therapy increases serum free 1, 25-dihydroxyvitamin D3: a 1-year prospective study. Clin Endocrinol1999; 50: 511–516.
35.
TremollieresFAPouillesJMRibotC: Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporosis Int2000; 12: 385–390.
36.
KhastgirGStuddJHollandNAlaghband-ZadehJSimsTJBaileyAJ: Anabolic effect of long-term estrogen replacement on bone collagen in elderly postmenopausal women with osteoporosis. Osteoporosis Int2001; 12: 465–470.
37.
RizzoliRBonjourJP: Determinants of peak bone mass and mechanisms of bone loss. Osteoporosis Int1999; 9 (suppl 2): S17–S23.
38.
ErshlerWBHarmanSMKellerET: Immunologic aspects of osteoporosis. Dev Comp Immunol1997; 21: 487–499.
39.
GirasoleGPasseriGJilkaRLManolagasSC: Interleukin-11: A new cytokine critical for osteoclast development. J Clin Invest1994; 93: 1516–1524.
40.
KimbleRB: Alcohol, cytokines, and estrogen in the control of bone remodeling. Alcohol Clin Exp Res1997; 21: 385–391.
41.
HogasenAKNordslettenLAasenAOFalchJA: There is no difference in spontaneous and 17-beta estradiol-induced interleukin-1 beta release by peripheral blood mononuclear cells from nonosteoporotic women with different rates of early postmenopausal bone loss. J Clin Endocrinol Metab1995; 80: 2480–2484.
42.
PumarinoHPumarinoMG: Cytokines, growth factors, and metabolic bone disease. Rev Med Chil1996; 124: 248–257.
43.
PacificiRBrownCPuscheckEFriedrichESlatopolskyEMaggioD: Effect of surgical menopause and estrogen replacement on cytokine release from human blood mono-nuclear cells. Proc Natl Acad Sci U S A1991; 88: 5134–5138.
44.
MundyGRBoyceBFYonedaT: Cytokines and bone remodeling. In: Osteoporosis (MarcusRFeldmanDKelseyJ eds). London: California Academic Press, 1996: pp302–310.
45.
van LeeuwenJPvan DrielMvan den BemdGJPolsHA: Vitamin D control of osteoblast function and bone extracellular matrix mineralization. Crit Rev Eukaryot Gene Expr2001; 11: 199–226.
46.
AkessonKLauKHBaylinkDJ: Rationale for active vitamin D analog therapy in senile osteoporosis. Calcif Tissue Int1997; 60: 100–105.
47.
PanichiVDe PietroSAndreiniBBianchiAMMiglioriMTaccolaD: Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium. Kidney Int1998; 54: 1463–1469.
48.
TsoukasCDWatryDEscobarSSProvvediniDMDinarelloCAHustmyerFG: Inhibition of interleukin-1 production by 1, 25-dihydroxyvitamin D3. J Clin Endocrinol Metab1989; 69: 127–133.
49.
RookGATaverneJLevetonCSteeleJ: The role of gamma-interferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis. Immunology1987; 62: 229–234.
50.
McKaneWRKhoslaSPetersonJMEganKRiggsBL: Circulating levels of cytokines that modulate bone resorption: Effects of age and menopause in women. J Bone Miner Res1994; 9: 1313–1318.
51.
ZhengSXVrindtsYLopezMDe GrooteDZangerlePFColletteJ: Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas1997; 26: 63–71.
